The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

• Status: Completed
• Trial end date: 2021-03-19
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the hemodynamic effects of PACAP38 after glibenclamide administration.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Glyburide; Pituitary Adenylate Cyclase-Activating Polypeptide

Criteria

Inclusion Criteria:

• Healthy volunteers of both sexes.

• 18-60 years.

• 50-100 kg.

• Women of childbearing age must use adequate contraception

Exclusion Criteria:

• A history of serious somatic or psychiatric disease

• Migraine or any other type of headache (except episodic tension-type headache less than 5 days per month)

• Daily intake of any medication except contraceptives